# BiomX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomx

- Industry: Biotechnology
- Headquarters: Ness Ziona, Israel
- Website: www.biomx.com/
- Total disclosed funding: $56M
- Latest round: Series B (Feb 20, 2019)
- Investors on record: 12

## About

Based in Ness Ziona, Israel, and founded in 2015 by co-founders Eran Elinav, Ph.D., Rotem Sorek, Ph.D., and Timothy Lu, MD, BiomX Inc. operates as a provider of phage therapy solutions targeting harmful bacteria in chronic diseases for patients with conditions like cystic fibrosis and diabetic foot osteomyelitis. In March 2024, BiomX Inc. raised USD 50.01 million in PIPE funding led by Deerfield Management and the AMR Action Fund, with participation from Nantahala Capital Management, the Cystic Fibrosis Foundation, and OrbiMed Advisors. As of 2024, the company is led by its CEO, Jonathan Solomon.

The company provides a wide range of phage therapy products to target and eradicate harmful bacteria in chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Moreover, the firm develops natural and engineered phage cocktails and customizes phage compositions based on proprietary bacterial targets. Additionally, the company also provides personalized treatments and biomarker discovery services.

## Funding rounds

- Series B, Feb 20, 2019, $32M — OrbiMed Advisors, Seventure Partners, Johnson & Johnson Innovation, Consensus Business Group, KB Investment, Takeda Ventures, Mirae Asset Venture Investment, 8VC, Handok Inc., RM Global Partners, SBI JI Innovation Advisory, Chong Kun Dang Pharm.
- Series A, May 15, 2017, $24M — OrbiMed Advisors, Seventure Partners, Johnson & Johnson Innovation, Takeda Ventures, Mirae Asset Venture Investment, SBI JI Innovation Advisory

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A, Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A, Series B
- SBI JI Innovation Advisory (https://capitalatlas.ai/funds/sbi-ji-innovation-advisory) — Series A, Series B
- Consensus Business Group — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series B
- Handok Inc. — Series B
- RM Global Partners (https://capitalatlas.ai/funds/rm-global-partners) — Series B
- Chong Kun Dang Pharm. — Series B